Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

carbamazepine) extended-release capsules

DAYTRANA(TM) (methylphenidate transdermal system)

ELAPRASE(R) (idursulfase)

FOSRENOL(R) (lanthanum carbonate)

INTUNIV(TM) (guanfacine) extended release

LIALDA(TM) (mesalamine)

MEZAVANT(R) (mesalazine)

REMINYL(R) (galantamine hydrobromide) (UK and Republic of Ireland)

REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of Ireland)

REPLAGAL(R) (agalsidase alfa)

VYVANSE(TM) (lisdexamfetamine dimesylate)

XAGRID(R) (anagrelide hydrochloride)

The following are trademarks of third parties referred to in this press release:

3TC (lamivudine) (trademarks of GlaxoSmithKline (GSK))

AMIGAL (migalastat hydrochloride) (trademark of Amicus)

COMBIVIR (lamivudine) (trademark of GSK)

DYNEPO (epoetin delta) (trademark of Sanofi Aventis)

EPIVIR (lamivudine) (trademark of GSK)

EPZICOM (lamivudine) (trademark of GSK)

JUVISTA (trademark of Renovo)

PENTASA (mesalamine) (trademark of Ferring)

PLICERA (isofagomine tartrate) (trademark of Amicus)

RAZADYNE (galantamine) (trademark of Johnson & Johnson)

RAZADYNE ER (galantamine) (trademark of Johnson & Johnson)

REMINYL (galantamine) (trademark of Johnson & Johnson, excluding UK and

Republic of Ireland)

REMINYL XL (galantamine) (trademark of Johnson & Johnson, excluding UK

and Republic of Ireland)

SOLARAZE (diclofenac sodium (3%w/w)) (trademark of Almirall)

VANIQA (eflornithine hydrochloride) (trademark of Almirall)

ZEFFIX (lamivudine) (trademark of GSK)

Overview of US GAAP Financial Results

1. Introduction

Summary of 2007 Revenues from continuing operations for the year to December 31, 2007 increased by 36% to $2,436.3 million (2006: $1,796.5 million).

Operating loss for the year to December 31, 2007 was $1,379.1 million (2006: income of $283.2 million). The loss in 2007 primarily ar
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ) ... Innovations in Smart Fabrics (Technical Insights)" report ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service titled ... assessment on technological advancements and market for Smart ... 1. The Smart Fabrics market is expected to ...
(Date:12/19/2014)... 2014 Today, TiFiber, Inc. ... production facility and future company headquarters in Fort ... new materials that safely and effectively control dangerous ... of its historic, strong support for manufacturing, but ... leading edge, technology-based companies such as TiFiber. ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... Mass., Aug. 9, 2011 Arthrosurface, Inc. ( ... systems, announced that it has performed its first ... glenoid system and its existing HemiCAP® ... the labrum intact and is implanted using an ...
... SAN DIEGO, Aug. 9, 2011 ViaCyte, Inc. today ... appointment of Allan Robins, Ph.D., as Acting Chief Executive ... Chief Scientific Officer. Robins continues to serve ... appointment as acting CEO follows the departure of President ...
... PITTSBURGH, Aug. 8 Researchers at the University of ... process of tooth enamel biomineralization, which could lead to ... reported online this week in the Proceedings of ... is the most mineralized tissue in the body and ...
Cached Biology Technology:Arthrosurface Launches World's First Easy Access Glenoid Resurfacing System 2ViaCyte Announces Executive Management Changes 2
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Iowa researchers and colleagues in France have identified a ... rhythm disorder called sinus node disease. Also known as ... 600 heart patients older than 65 and is responsible ... placements in the United States. While the ...
... red wine may decrease the risk of lung cancer ... issue of Cancer Epidemiology, Biomarkers & Prevention ... "An antioxidant component in red wine may ... Chun Chao, Ph.D., a research scientist at Kaiser Permanente ...
... Institute researchers have developed a new prenatal blood test ... chromosomal defects in a small study of 18 pregnant ... test would offer a safer and faster alternative to ... small risk of miscarriage., Researchers have long known that ...
Cached Biology News:Study provides insight on a common heart rhythm disorder 2Study provides insight on a common heart rhythm disorder 3Red wine may lower lung cancer risk 2New blood test for Down syndrome 2New blood test for Down syndrome 3New blood test for Down syndrome 4
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
...
... increasingly essential for reducing sample and ... other biochemical applications. The eight-channel nano25 ... in the industry. ,Features: , ... dispensed volumes , Automated diagnostics detect ...
Biology Products: